BACKGROUND: Hepatocellular carcinoma (HCC) causes premature death and loss of life expectancy worldwide. Its primary and secondary prevention can result in a significant number of years of life saved. AIM: To assess how many years of life are lost after HCC diagnosis. METHODS: Data from 5346 patients with first HCC diagnosis were used to estimate lifespan and number of years of life lost after tumour onset, using a semi-parametric extrapolation having as reference an age-, sex- and year-of-onset-matched population derived from national life tables. RESULTS: Between 1986 and 2014, HCC lead to an average of 11.5 years-of-life lost for each patient. The youngest age-quartile group (18-61 years) had the highest number of years-of-life lost, representing approximately 41% of the overall benefit obtainable from prevention. Advancements in HCC management have progressively reduced the number of years-of-life lost from 12.6 years in 1986-1999, to 10.7 in 2000-2006 and 7.4 years in 2007-2014. Currently, an HCC diagnosis when a single tumour <2 cm results in 3.7 years-of-life lost while the diagnosis when a single tumour ≥2 cm or 2/3 nodules still within the Milan criteria, results in 5.0 years-of-life lost, representing the loss of only approximately 5.5% and 7.2%, respectively, of the entire lifespan from birth. CONCLUSIONS: Hepatocellular carcinoma occurrence results in the loss of a considerable number of years-of-life, especially for younger patients. In recent years, the increased possibility of effectively treating this tumour has improved life expectancy, thus reducing years-of-life lost.

Years of life that could be saved from prevention of hepatocellular carcinoma / Cucchetti, A; Trevisani, F; Bucci, L; Ravaioli, M; Farinati, F; Giannini, Eg; Ciccarese, F; Piscaglia, F; Rapaccini, Gl; Di Marco, M; Caturelli, E; Zoli, M; Borzio, F; Sacco, R; Maida, M; Felder, M; Morisco, F; Gasbarrini, A; Gemini, S; Foschi, Fg; Missale, G; Masotto, A; Affronti, A; Bernardi, M; Pinna, AD; Italian Liver Cancer (ITA.LI.CA.) Group; Bolondi, L; Biselli, M; Caraceni, P; Domenicali, M; Gramenzi, A.. - In: ALIMENTARY PHARMACOLOGY AND THERAPEUTICS. - ISSN 1365-2036. - STAMPA. - 43:(2016), pp. 814-824. [10.1111/apt.13554]

Years of life that could be saved from prevention of hepatocellular carcinoma.

CUCCHETTI, ALESSANDRO;TREVISANI, FRANCO;BUCCI, LAURA;RAVAIOLI, MATTEO;CICCARESE, FEDERICA;PISCAGLIA, FABIO;ZOLI, MARCO;BERNARDI, MAURO;PINNA, ANTONIO DANIELE;BOLONDI, LUIGI;BISELLI, MAURIZIO;CARACENI, PAOLO;DOMENICALI, MARCO;GRAMENZI, ANNAGIULIA
2016

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) causes premature death and loss of life expectancy worldwide. Its primary and secondary prevention can result in a significant number of years of life saved. AIM: To assess how many years of life are lost after HCC diagnosis. METHODS: Data from 5346 patients with first HCC diagnosis were used to estimate lifespan and number of years of life lost after tumour onset, using a semi-parametric extrapolation having as reference an age-, sex- and year-of-onset-matched population derived from national life tables. RESULTS: Between 1986 and 2014, HCC lead to an average of 11.5 years-of-life lost for each patient. The youngest age-quartile group (18-61 years) had the highest number of years-of-life lost, representing approximately 41% of the overall benefit obtainable from prevention. Advancements in HCC management have progressively reduced the number of years-of-life lost from 12.6 years in 1986-1999, to 10.7 in 2000-2006 and 7.4 years in 2007-2014. Currently, an HCC diagnosis when a single tumour <2 cm results in 3.7 years-of-life lost while the diagnosis when a single tumour ≥2 cm or 2/3 nodules still within the Milan criteria, results in 5.0 years-of-life lost, representing the loss of only approximately 5.5% and 7.2%, respectively, of the entire lifespan from birth. CONCLUSIONS: Hepatocellular carcinoma occurrence results in the loss of a considerable number of years-of-life, especially for younger patients. In recent years, the increased possibility of effectively treating this tumour has improved life expectancy, thus reducing years-of-life lost.
2016
Years of life that could be saved from prevention of hepatocellular carcinoma / Cucchetti, A; Trevisani, F; Bucci, L; Ravaioli, M; Farinati, F; Giannini, Eg; Ciccarese, F; Piscaglia, F; Rapaccini, Gl; Di Marco, M; Caturelli, E; Zoli, M; Borzio, F; Sacco, R; Maida, M; Felder, M; Morisco, F; Gasbarrini, A; Gemini, S; Foschi, Fg; Missale, G; Masotto, A; Affronti, A; Bernardi, M; Pinna, AD; Italian Liver Cancer (ITA.LI.CA.) Group; Bolondi, L; Biselli, M; Caraceni, P; Domenicali, M; Gramenzi, A.. - In: ALIMENTARY PHARMACOLOGY AND THERAPEUTICS. - ISSN 1365-2036. - STAMPA. - 43:(2016), pp. 814-824. [10.1111/apt.13554]
Cucchetti, A; Trevisani, F; Bucci, L; Ravaioli, M; Farinati, F; Giannini, Eg; Ciccarese, F; Piscaglia, F; Rapaccini, Gl; Di Marco, M; Caturelli, E; Zoli, M; Borzio, F; Sacco, R; Maida, M; Felder, M; Morisco, F; Gasbarrini, A; Gemini, S; Foschi, Fg; Missale, G; Masotto, A; Affronti, A; Bernardi, M; Pinna, AD; Italian Liver Cancer (ITA.LI.CA.) Group; Bolondi, L; Biselli, M; Caraceni, P; Domenicali, M; Gramenzi, A.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/561336
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 19
social impact